论文部分内容阅读
表皮生长因子受体(Epidermal growth factor receptor,EGFR)及其配体在多种肿瘤细胞中高表达,免疫注射表皮生长因子(Epidermal growth factor,EGF)-载体蛋白所产生的抗体能够干扰EGFR与EGF的相互作用,进而抑制肿瘤生长。本实验室设计了EGF和TGFα的嵌合配体E5T,并将具有免疫增强作用的葡萄球菌肠毒素A(Staphylococcal enterotoxin A,SEA)与之融合。融合蛋白在大肠杆菌内表达后,通过金属螯合亲和层析,得到了纯度较高的E5T-mSEA融合蛋白。将E5T-mSEA免疫小鼠,能够产生高滴度的抗体,该抗体能够同时识别EGF和TGFα。将抗E5T-mSEA免疫血清与肿瘤细胞共培养,在1:10的稀释度下能显著抑制EGFR阳性肿瘤细胞的生长,而对EGFR阴性肿瘤细胞293T的生长没有明显影响。
Epidermal growth factor receptor (EGFR) and its ligand are highly expressed in a variety of tumor cells. Antibodies produced by immunization with Epidermal growth factor (EGF) Interaction, thereby inhibiting tumor growth. Our laboratory designed a chimeric ligand E5T for EGF and TGFα, and fused it with Staphylococcal enterotoxin A (SEA). After the fusion protein was expressed in E. coli, the high purity E5T-mSEA fusion protein was obtained by metal chelate affinity chromatography. E5T-mSEA immunized mice were able to generate high titers of antibodies that recognized both EGF and TGFα. The co-culture of anti-E5T-mSEA serum with tumor cells significantly inhibited the growth of EGFR-positive tumor cells at a dilution of 1:10 and had no significant effect on the growth of EGFR-negative tumor cells 293T.